Separately, in a phase 2 study, the anti-PD-1 inhibitor pembrolizumab (Keytruda) was investigated as second-line therapy in patients with advanced HCC following sorafenib failure (Zhu et al., 2018). Here, PDCD1 is linked to hepatocellular carcinoma.